于2025年12月11日，China Vista Capital向BE Fortune Diversified Income Fund SP 2("基金")之基金经理递 交赎回申请表，要求赎回其于基金持有的全部8,020.99股A类股份(「股份」)。 格隆汇12月31日丨北京健康(02389.HK)宣布，于2025年12月31日，公司间接全资附属公司China Vista Capita作为基金单位持有人，接获赎回确认并赎回其于基金股份的投资，赎回总值约1091.6万美元(约 8514.5万港元)，将部分以现金及部分以实物分派之形式结算，实物分派为应收公司附属公司1121695 B.C.Ltd.的贷款连同应计利息。与2024年12月31日投资基金之公平值相比，集团估计就赎回事项将变现 合共约104.4万美元(约814.3万港元)的收益。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 （於開曼群島註冊成立的有限公司） （股份代號： ） 2389 – 1 – 背 景 茲提述本公司日期分別為二零二零年八月三日及二零二零年八月七日內容有 關（其 中 包 括）認 購 基 金 權 益 之 公 告（「該等公告」）。除 另 有 指 明 外，本 公 告 所 用 詞 彙 與 該 等 公 告 所 界 定 者 具 有 相 同 涵 義。 於 二 零 二 五 年 十 二 月 三 十 一 日，本 公 司 之 間 接 全 資 附 屬 公 司China Vista Capital Holding Limited（「China Vista Capital」）作 為 基 金 單 位 持 有 人，接 獲 贖 回 確 認 並 贖 回 其 於 基 金 股 份 之 投 資，贖 回 總 值 約10,916,000美 元（約85,145,000港 元），將 部 分 以 現 金 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 呈交日期: 2025年12月31日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02389 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.2 HKD | | | 2,000,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.2 HKD | | | 2,000,000,000 | 本月底法定/註冊股本總額： HKD 2,000,000,000 FF301 第 1 頁 共 10 頁 v 1.1.1 ...

Core Insights - As of December 10, 30 stocks reached their 52-week highs, with Design Metropolis (01545), Platinum Holdings (00459), and China Boton (03318) leading the increase rates at 40.82%, 35.48%, and 30.23% respectively [1][2] 52-Week Highs - Design Metropolis (01545) closed at 0.124, with a peak of 0.138, achieving a high rate of 40.82% [1] - Platinum Holdings (00459) closed at 0.121, with a peak of 0.126, achieving a high rate of 35.48% [1] - China Boton (03318) closed at 2.090, with a peak of 2.800, achieving a high rate of 30.23% [1] - Other notable stocks include: - China New Holdings (08125) at 25.00% [1] - Qiaoyang International Holdings (08070) at 14.46% [1] 52-Week Lows - The stock with the largest decline was Jingye Mingbang Group (02231), which fell to 0.099, a decrease of 26.40% [2] - Other significant declines included: - Zhonggang Petroleum (00632) at -16.40% [2] - Guofu Hydrogen Energy (02582) at -13.31% [2] - Additional stocks with notable declines: - Haotian International Construction Investment (01341) at -11.11% [2] - Jiaming Group Holdings (01271) at -10.00% [2]

正值《中华人民共和国招标投标法》颁布施行25周年之际，为进一步规范家具招标采购秩序，树立诚信 标杆典范，引导行业健康持续发展，中国采购与招标网、中国名企排行网组织开展了"2025(第15届)家 具招标采购评价推介活动"。该活动历时2个多月，历经企业申报、资料提交、数据核对、综合评审等阶 段，依据家具招标投标大数据及科学合理的家具招标采购综合评价法，遴选出"2025适老家具十大品 牌"。 中国采购与招标网、中国名企排行网在家具招标采购综合评价中主要从以下七个维度进行考量：一是考 量企业的中标项目总数量及中标总金额，这是家具招标采购评价中最核心的指标；二是考量企业的研发 投入和产学研结合情况；三是品牌建设与市场竞争力；四是数智化转型与供应链管理；五是绿色环保与 可持续发展；六是组织管理与文化创新；七是市场拓展与服务能力。 在我国每年40多万亿元的公共采购中，家具是其中一个重要的品类。2024年，我国家具的采购规模就达 184.36亿元，较2023年略有下降，但依旧保持较高的采购规模。这些榜单发布后，将成为公共采购比选 适老家具的重要参考依据。以下是中国采购与招标网、中国名企排行网对"2025适老家具十大品牌"的详 ...

致：香港交易及結算所有限公司 公司名稱: 北京健康(控股)有限公司 呈交日期: 2025年12月2日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02389 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.2 HKD | | | 2,000,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.2 HKD | | | 2,000,000,000 | ...

Core Viewpoint - Beijing Health (02389.HK) has entered into a supplemental agreement to amend certain terms of the shareholders' agreement and established a concerted action agreement with Jinfu regarding the target company, 1121695 B.C. Ltd, which will lead to the target company becoming a subsidiary of Beijing Health [1][2]. Group 1 - The concerted action agreement allows Beijing Health and Jinfu to act in unison at the target company's shareholder meetings, controlling approximately 78.15% of the equity interests [2][4]. - The target company's board will consist of three directors, with Beijing Health entitled to nominate two, thereby controlling the majority of the board [2][3]. - Following the amendments and agreements, the target company will be classified as a majority-controlled subsidiary, and its financial performance will be consolidated into Beijing Health's financial statements [2][4]. Group 2 - The target company is registered under British Columbia law and is primarily engaged in property holding, with its main asset being Royal Towers, a mixed-use complex that includes 135 residential units and approximately 20,848 square feet of commercial space [3][4]. - Beijing Health currently holds a 47.47% stake in the target company and has provided multiple rounds of financial support for its operations [4]. - The day-to-day operations and strategic planning of the target company are overseen by personnel appointed by Beijing Health, enhancing operational control and efficiency [4].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 （於開曼群島註冊成立的有限公司） （股份代號： ） 2389 須予披露交易 視作收購附屬公司 背 景 根 據 股 東 協 議 補 充 文 件，目 標 公 司 之 董 事 會 由 三 名 董 事 組 成，其 中 本 公 司 有 權 提 名 兩 名 董 事。本 公 司 提 名 目 標 公 司 董 事 後，將 控 制 目 標 公 司 董 事 會 大 多 數 成 員 的 組 成。此 外，根 據 一 致 行 動 協 議，本 公 司 與 金 富 同 意 於 目 標 公 司 股 東 大 會 投 票 時，就 其 於 目 標 公 司 合 共 約78.15%的 股 權 權 益 採 取 一 致 行 動， 據 此，金 富 承 諾，就 任 何 一 致 行 動 事 項 而 言，應 與 本 公 司 諮 詢 及╱或 磋 商， 並 按 本 公 司 的 指 示 投 票（或 促 使 投 ...

Core Insights - The forum on "Medical Device Technology Review and High-Quality Development" highlighted the rapid growth and innovation in Beijing's medical device industry, with a projected revenue exceeding 1 trillion yuan in 2024 [1][3] - Beijing has established itself as a national innovation hub for the pharmaceutical industry, with over 81 approved Class III innovative medical devices, accounting for more than 20% of the national total [1][3] - The city is leading in the number of artificial intelligence medical products and surgical robots, further solidifying its position in the medical device sector [1][3] Industry Development - The medical device industry is increasingly recognized for its importance in the health sector, with Beijing forming significant advantages through policy support and industry collaboration [3] - As of 2024, the medical device industrial output value is expected to reach 48 billion yuan, with retail and wholesale values at 390 billion yuan [3] - The Beijing Drug Administration has implemented measures to streamline the review and approval process, reducing the average review time for Class II medical devices to 43 working days [3] Innovation and Regulation - The Beijing Economic and Technological Development Area (Yizhuang) is a key area for the development of the medical and health industry, housing over 5,000 enterprises and accounting for nearly half of the city's output [4] - Yizhuang has entered 56 products into the national special review process for innovative medical devices, with 25 approved for market launch [4] - The area aims to create a world-class medical device industry cluster through a dual-driven approach of foreign investment and local ecosystem development [5] Expert Support and Collaboration - The National Medical Products Administration's Medical Device Technical Review Center has over 2,500 experts, including 41 academicians, providing technical support for the review process [6] - A collaborative platform for innovative biomaterials was established to address critical issues in the field, emphasizing the strategic importance of mastering core technologies [7] Clinical Applications - The forum discussed the regulatory focus on specific medical devices, such as orthokeratology lenses, with domestic products accounting for two-thirds of the market [8] - Artificial intelligence medical devices are generating numerous clinical application scenarios, enhancing medical supply capabilities and optimizing treatment processes [9]

Core Viewpoint - Beijing Health (02389) announced the resignation of Mr. Xiao Jianwei as the executive director of the company, effective from October 10, 2025, due to regulatory actions by the Stock Exchange [1] Group 1 - Mr. Xiao Jianwei's resignation is a direct result of regulatory actions taken by the Stock Exchange [1] - The effective date of the resignation is set for October 10, 2025 [1]